HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma

Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 2, 2009, Pages 228-234

  Nichols, Anthony C ^a   Faquin, William C ^b   Westra, William H ^c   Mroz, Edmund A ^b,d   Begum, Shanaz ^c   Clark, John R ^b   Rocco, James W ^a,b,d  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTENSITY MODULATED RADIATION THERAPY; MALE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STAINING; TREATMENT OUTCOME; TUMOR CELL; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 59249090693     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.11.025     Document Type: Article

References (25)

1. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100 (2008) 407-420
2. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008) 261-269
3. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31 (2004) 744-754
4. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 (2005) 467-475
5. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26 (2008) 3128-3137
6. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 (2006) 2606-2611
7. Herrero R., Castellsague X., Pawlita M., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95 (2003) 1772-1783
8. Huang C.C., Qiu J.T., Kashima M.L., et al. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol 11 (1998) 971-977
9. Begum S., Gillison M.L., Ansari-Lari M.A., et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9 (2003) 6469-6475
10. Goldenberg D., Begum S., Westra W.H., et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 30 (2008) 898-903
11. Cancer of the Oral Cavity and Pharynx for selected subsites (Invasive). http://seer.cancer.gov/cgi-bin/csr/1975_2005/sect_20_table.06B Accessed: 7/6/July 6, 2008
12. Connolly G.N., and Alpert H.R. Trends in the use of cigarettes and other tobacco products, 2000-2007. JAMA 299 (2008) 2629-2630
13. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
14. Moore C. Cigarette smoking and cancer of the mouth, pharynx, and larynx. A continuing study. JAMA 218 (1971) 553-558
15. Worden F.P., Kumar B., Lee J.S., et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26 (2008) 3138-3146
16. Rocco J.W., and Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264 (2001) 42-55
17. Mroz E.A., Baird A.H., Michaud W.A., et al. COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res 68 (2008) 6049-6053
18. Klaes R., Friedrich T., Spitkovsky D., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92 (2001) 276-284
19. Nakao Y., Yang X., Yokoyama M., et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 75 (1997) 1410-1416
20. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
21. Reimers N., Kasper H.U., Weissenborn S.J., et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120 (2007) 1731-1738
22. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
23. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008) 2013-2019
24. Cutts F.T., Franceschi S., Goldie S., et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 85 (2007) 719-726
25. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702